Cancer carbohydrates are now a key target for the development of effective and safe cancer vaccines. To investigate the most effective anti-cancer strategies, CD BioGlyco focuses on the development of tumor-associated carbohydrate antigens (TACAs)-based cancer vaccines for many years. We are confident to be your scientific assistant in the field of vaccine development.

Tumor-Associated Carbohydrate Vaccine

Cancer cells can be distinguished from normal cells by displaying abnormal types and levels of carbohydrate structures on the surface of cancer cells. These carbohydrate structures are known as TACA, which are considered promising targets for the design of anti-cancer vaccines. This vaccine can be recognized by the immune system and produce an immune response. Antibodies produced against carbohydrate antigens participate in the inactivation of carbohydrate-modified cancer cells by slowing tumor cell growth and inducing apoptosis.

However, most carbohydrate antigens are T cell-independent and produce weak immune responses. In addition, it is easy to induce immune tolerance and immunosuppression due to the endogenous nature of naturally occurring TACAs, which increases the challenge of their application in cancer vaccines. To enhance immunogenicity, researchers usually couple them with carrier proteins or chemically modify them. Currently, multiple heterogeneous populations of TACA expressed in tumors may represent the most effective anticancer strategy.

Fig.1 Immunological response to carbohydrate antigens. (a). Carbohydrates bind B-cell receptors, initiating a weak T-cell independent response. (b). Induction of T-cell-dependent response by conjugated vaccines. (Feng, 2016)

Our Solutions

To enhance immunogenicity and overcome the difficulties associated with immune tolerance and immunosuppression, CD BioGlyco provides customers with the following solutions:

• Covalently coupling of TACAs to appropriate vectors, such as keyhole limpet haemocyanin (KLH), to enhance immunogenicity, including clustered or multivalent conjugate vaccines.
• Coupling TACAs to T-cell peptide epitopes or/and built-in adjuvants to form multicomponent glycoconjugate vaccines. Optimizing vaccine formulations based on built-in adjuvants or innovative delivery systems may significantly improve the utilization of available carbohydrate antigens.
• Development of vaccines based on chemically modified TACAs in combination with metabolic engineering of cancer cells.

Applications

• Prevention of melanoma, breast cancer, pancreatic cancer, and ovarian cancer.
• Open new perspectives for some diseases which are lacking efficacious preventative or therapeutic vaccines.
• Development of safe and efficient therapeutic vaccines against tumor.

Advantages of Us

• Simplicity of preparation
• Longtime of immune stimulation
• High purity products
• Strict quality control

With advanced experimental platforms and researchers with professional knowledge in the field of chemistry and biology, CD BioGlyco assists customers in the development of promising carbohydrate antigen carriers and clinical trials to ensure that they reach the maximum and desired immune response level. If you need our services, please feel free to contact us.

References:

1. Jin, K.T.; et al. Recent advances in carbohydrate-based cancer vaccines. Biotechnology Letters. 2019, 41(6-7):641-650.
2. Feng, D.; et al. Recent advance in tumor-associated carbohydrate antigens (TACAs)-based antitumor vaccines. Acs Chemical Biology. 2016, 11(4):850-63.